TG Therapeutics, Inc.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS7
PHASE 3 / 2-34
RECRUITING5
READOUTS ≤12 MONTHS2
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Ublituximab NCT07211633 |
P3 | Active, not recruiting | Relapsing Multiple Sclerosis | 360 | 2026-10-31 (-2 mo) |
| ENHANCE NCT05877963 |
P3 | Recruiting | Relapsing Multiple Sclerosis | 800 | 2027-01-21 (+20 mo) |
| Ublituximab NCT07503873 |
P2 | Recruiting | Multiple Sclerosis | 350 | 2027-07-31 |
| Ublituximab NCT07673744 |
P2 | Recruiting | Myasthenia Gravis | 120 | 2028-07-01 |
| Ublituximab NCT07680946 |
P2 | Recruiting | Schizophrenia | 60 | 2028-12-12 |
| Ublituximab NCT07220252 |
P2/3 | Recruiting | Relapsing Multiple Sclerosis | 240 | 2030-01-01 |
| Ublituximab NCT04130997 |
P3 | Active, not recruiting | Relapsing Multiple Sclerosis (RMS) | 1100 | 2032-05-31 (+104 mo) |